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Abstract: Acute coronary syndromes comprise a large spectrum of clinical conditions ranging 
from unstable angina pectoris to acute ST-elevation myocardial infarction. Chest pain is usually 
the major symptom of atherosclerotic heart disease; however, it may be challenging to diagnose 
correctly, especially in the emergency department, because of the ambiguous way that pain is 
characterized by some patients. Cardiac troponins are sensitive and specific biomarkers used in 
the diagnosis of myocardial infarction that are released into the bloodstream when cardiac myo-
cytes are damaged by acute ischemia or any other mechanism. They are the cornerstone for the 
diagnosis, risk assessment, prognosis, and determination of antithrombotic and revascularization 
strategies. However, troponin elevation indicates the presence, not the mechanism, of myocardial 
injury. There are many clinical conditions other than myocardial infarction that cause troponin 
elevation; thus, the physician should be aware of the wide spectrum of disease states that may 
result in troponin elevation and have a clear understanding of the related pathophysiology to 
effectively make a differential diagnosis. This review focuses on causes of troponin elevation 
other than acute coronary syndromes.
Keywords: cardiac troponin, troponin elevation without acute coronary syndrome, differential 
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Introduction
Acute coronary syndromes constitute a large spectrum of clinical conditions ranging 
from unstable angina pectoris to acute ST-elevation myocardial infarction. Chest pain 
is usually the major symptom of atherosclerotic heart disease; however, it may be 
challenging to diagnose correctly, especially in the emergency department, because of 
the ambiguous way that some patients characterize their pain. Cardiac serum markers, 
especially cardiac troponins (cTns), are the cornerstone of the diagnosis, risk assess-
ment, prognosis, and determination of antithrombotic and revascularization strategies. 
Physicians should be aware of the wide spectrum of disease states that may result in 
elevation of cTns and have a clear understanding of the related pathophysiology to 
effectively make a differential diagnosis. This review focuses on causes of troponin 
elevation other than acute coronary syndromes. Pubmed Central and Cochrane Library 
were browsed for related topics.
Cardiac troponins consist of three proteins known as cTnC, cTnI, and cTnT1 that 
interact with tropomyosin to form the troponin-tropomyosin complex. This complex 
forms the skeleton of the striated muscle and has a regulatory function in the excitation-
contraction coupling of the heart. If heart muscle cells are damaged by acute ischemia 
or any other mechanism, these proteins are released into the bloodstream.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The European Society of Cardiology/American College 
of Cardiology Joint Committee has redefined myocardial 
infarction (MI) to be an elevation of serum cTn above the 
99th percentile of the healthy reference population in the 
presence of ischemic signs and symptoms.2 In addition, 
a rising and/or falling troponin pattern is an important com-
ponent of the universal definition of MI. The major limita-
tion of the standard cTn assays is their low sensitivity in the 
first few hours after MI at the time of the first presentation in 
the patient due to a delayed increase in the circulating levels 
of cTns. The diagnosis may take 6–12 hours of monitor-
ing and serial blood sampling, which delays diagnosis and 
probably increases morbidity and mortality.3 To overcome 
this issue, highly sensitive cTn assays have been developed 
that can detect cTn levels well below the 99th percentile 
of the normal reference population.4 However, increased 
sensitivity comes at the cost of decreased specificity. 
Although the availability of highly sensitive assays allows 
for the earlier detection of MI, the number of patients with 
detectable cTn values in the emergency department or other 
in-hospital settings increases substantially as a result, which 
challenges the clinician to make a differential diagnosis. 
With these new assays in particular, nonischemic causes of 
troponin elevation should be kept in mind since troponin 
elevation indicates the presence, not the mechanism, of 
myocardial injury.
Noncardiac causes of troponin 
elevation
Chronic renal failure
Acute coronary syndromes are frequently observed in 
renal failure; however, the use of troponin for diagnosis 
is inconvenient since cTn levels may be elevated in the 
absence of an acute ischemic event.5–7 Mortality remains 
high in end-stage renal disease despite dialysis therapy; 
  approximately 50% of these deaths are due to cardiac 
causes.8–10   Electrocardiography (ECG) may not be reliable 
in most of these patients because intraventricular conduction 
defects and left ventricular hypertrophy are very common. 
Troponins are commonly used as prognostic indicators in 
end-stage renal disease although troponins and creatinine 
kinase-myocardial band (CKMB) may show false positivity 
in this group as mentioned elsewhere.11 In acute myocardial 
injury, slightly elevated troponin levels may be detected 
but creatinine kinase (CK) and CKMB levels remain in the 
reference range. This finding is due to the unbound fraction 
of troponins in the cytoplasm of the cardiac myocytes, which 
is approximately 6% of cTnT and 3% of cTnI.12 Although it 
remains to be proven, it is thought that the unbound fraction 
increases in renal failure.
Some animal experiments have shown that trauma and 
stress induce the cTnT isoform in skeletal muscle. It is 
speculated that chronic skeletal muscle damage and inflamma-
tion in dialysis patients induce cTnT in a similar way.13–15
Heart failure is also a common comorbidity in renal 
failure, in which troponins increase without any evidence 
of ischemia or infarct.16
Decreased clearance is another proposed explanation 
for troponin elevation in renal failure;17 however, troponins 
are large macromolecules like CK, CKMB, and albumin 
that are cleared by the reticuloendothelial system. Recent 
studies suggest that cardiac troponins are fragmented into 
immunoactive particles of 8–25 kDa in length that are quite 
sensitive to immunoassays.18 Although these fragments are 
small enough to be cleared by healthy kidneys, renal impair-
ment leads to clearance decrease. The healthy human heart 
is always prone to microloss of cardiac myocytes but, when 
renal failure is involved, clearance of troponin fragments due 
to routine myocyte loss is impaired.
In renal failure, cTnT elevation is seen more frequently 
than cTnI. cTnI is less stable in the blood and is more prone 
to chemical changes in addition to higher rates of clearance 
during dialysis; as a result, it is thought to have an advantage 
over cTnT in patients with renal impairment.19
Advanced heart failure
Patients with acute heart failure/acute pulmonary edema 
constitute an important proportion of emergency   department 
admissions. Troponin levels may rise without overt ischemia 
in heart failure.20,21 This phenomenon was first reported by 
Missov and Calzolari.22 In another study by the same group, 
it was concluded that myocyte injury in the chronically 
damaged myocardium results in damage of the contractile 
proteins, which consequently causes protein leakage to the 
circulation.23 Sato et al have reported dismal prognoses in 
patients with nonischemic heart failure with the highest 
  percentile of admission cTnT levels, although they were 
treated with optimal medical therapy.21 This was associated 
with the ongoing subclinical myocardial damage within the 
subgroup with the highest admission cTnT levels.   Troponin 
positivity was reported to be 10.4% and 92% using standard 
and highly sensitive cTnT assays, respectively, in 4053 
chronic heart failure patients enrolled in the Valsartan Heart 
Failure Trial (Val-HeFT).24 Many studies have reported that 
troponin can be used as predictor of mortality, especially 
when ultrasensitive assays are used.25,26Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Cerebrovascular accidents
Subarachnoid hemorrhage (SAH)
The cardiac effects of intracardiac bleeding were first 
defined in 1903 by Cushing as alterations in blood pres-
sure and cardiac rhythm disturbances.27 Electrocardio-
graphic manifestations were first mentioned by Byer in 
1947.28 Several studies since then have shown the effects of 
hypothalamic stimulation on ECG and the cardiac rhythm 
in addition to the fact that myocardial injury was not 
mandatory for manifested electrocardiographic changes.29 
Earlier, it was believed that atherosclerotic coronary artery 
disease or coronary vasospasm was the basis of cardiac 
injury in subarachnoid bleeding, but this was not shown 
angiographically. Myocardial ischemia secondary to 
tachycardia and/or hypertension was the other proposed 
mechanism.
Today, the most widely accepted theory is the 
“catecholamine hypothesis.”30 Several autopsy studies 
have revealed petechial subarachnoid bleeding sites and 
histologically dense eosinophilic transverse bands in the 
myocardium. This phenomenon is termed “contraction 
band necrosis” and is detected in both patients with 
electrocardiographic changes and those with completely 
  normal ECGs. Similar lesions are also detectable in patients 
with pheochromocytoma or in animal experiments using 
stellate ganglion stimulation or catecholamine infusion.31 
An increase in plasma catecholamines of up to 30× is 
possible, but it is uncertain whether myocardial necrosis 
is related to the plasma catecholamine increase or to the 
catecholamine surge that is locally stimulated by cardiac 
nerves. It is possible that acute brain injury results in a 
massive release of norepinephrine from the myocardial 
sympathetic nerve terminals to the myocardial interstitium, 
which may subsequently lead to myocyte necrosis and 
contractile dysfunction in addition to sympathetic nerve 
terminal damage.
The latest studies have reported the rate of cardiac injury 
markers as being 20%–40% in the presence of subarachnoid 
bleeding.30,32 Approximately 10% of these patients have 
reversible segmental wall motion abnormalities that fit the 
distribution pattern of the myocardial sympathetic nerve 
terminals rather than the pattern of coronary artery disease. 
The most severe form of myocardial injury involving elevated 
myocardial injury markers is “neurogenic cardiogenic 
shock”33,34 accompanied by pulmonary edema.
Among patients with aneurysmal SAH, the subgroup 
with higher Hunt–Hess scores, which are used to grade 
the bleeding severity, had higher troponin I levels.35 
In another study, it was reported that functional recovery 
of the aneurysmal SAH patients with higher troponin levels 
was poor, and the sequela rates were higher.36 The authors 
conclude here that cTn also plays a role in predicting SAH 
prognosis.
ischemic cerebrovascular accident
Studies investigating troponin release in the course of ischemic 
cerebrovascular disease have reported contradictory results in 
contrast to studies on cerebral hemorrhage.   Troponin levels 
were found to be increased and had prognostic significance 
in some studies37,38 but not others.39,40 As a result, troponin 
cannot be reliably used as a prognostic indicator for ischemic 
cerebrovascular disease. The proposed mechanisms regarding 
troponin release in the early phase of ischemic cerebrovascular 
disease include secondary cardioembolic cerebral ischemia 
related to primary myocardial damage, secondary central 
nervous system activation to primary cerebral ischemia, and 
cerebral disease-related heart failure.
Acute pulmonary embolism
Acute massive or submassive pulmonary embolism is asso-
ciated with elevated serum cTn levels.41 Rates of troponin 
positivity have been reported as 16%–47% in several   studies, 
and troponin has been proposed as a risk determinant that 
may help in the decision of performing thrombolysis or 
embolectomy.42–44
Massive pulmonary embolism may cause cardiogenic 
shock and acute right ventricular dilatation. The sudden 
increase in oxygen demand of the right ventricle, increase in 
right ventricle intramural pressure, decrease in cardiac output, 
and release of endothelial mediators such as tromboxane, 
serotonin, and endothelin contribute to right ventricular 
ischemia and damage.45,46
Chronic obstructive pulmonary disease 
(COPD)
Cardiovascular risk factors and cardiac comorbidity are fre-
quent in patients with COPD. Troponin elevation was found 
to be an independent predictor of the need for noninvasive 
mechanical ventilation and mortality in patients who were 
admitted with acute exacerbation of COPD.47–49 The amount 
of energy and oxygen needed for respiration is increased in 
the acute exacerbation period; in addition, the left ventricular 
afterload is increased in relation with more negative intratho-
racic pressure. Worsened pulmonary hypertension, hypoxia, 
and hypercapnia also contribute to myocardial damage during 
the acute exacerbation period.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Acute noncardiac critical illness
The term “critically ill patient” refers to individuals who are 
hospitalized in intensive care units, patients who are typically 
elderly with multiple comorbid illnesses.50 However, some 
fragile older patients, who live alone or in nursing homes 
and are referred to emergency departments and subsequently 
hospitalized, may also be included in this category.
Studies of intensive-care-unit patients report that tro-
ponin is elevated in patients with increased myocardial 
demand due to multiple comorbid conditions, positive end 
expiration therapy, the need for inotropic support, or high 
body temperature; these patients typically have higher 
morbidity and mortality rates.51,52 Hypotension, anemia, 
and microocclusion impair oxygenation. Increased myo-
cardial oxygen demand, increased wall tension, hyperten-
sion, tachycardia, pulmonary embolism, or the presence 
of myocardial toxins in sepsis can cause minor myocardial 
damage. Troponin can be temporally elevated in some 
situations, a finding that is related to increased membrane 
permeability.53 The myocardial depressing factors released 
in sepsis and other inflammatory conditions cause troponin 
to be fragmented into low molecular weight particles in 
situ. These fragments are secreted into the circulation in 
the presence of increased membrane permeability. Since 
there is no necrosis, the myocyte damage is not permanent. 
Myocardial depression is completely reversible in patients 
who recover from sepsis.
Strenuous exercise
Competitive endurance sports have been suggested to be 
associated with elevations in cardiac biomarkers, especially 
cTns. Different human studies in the literature have reported 
a wide range of rates for troponin elevation, up to as much 
as 78%.54 Use of different generation assays with different 
cutoffs is the probable cause of this wide range of results. The 
pathophysiology and probable clinical impact of cTn eleva-
tion have been addressed in many studies, but a consensus 
does not exist. Middleton et al suggested that the increased 
myocardial demand related to endurance exercise could 
physiologically increase the turnover of cardiac   troponins.55 
Another proposal was that stress induces free radical over-
load, which causes a transient increase in membrane per-
meability and leads to troponin leakage from the cytosol.56 
A recent rat study supported this hypothesis in that it was 
shown that the temporal change in serum cTn was matched 
by an increase in the concentration of myocardial malondial-
dehyde, a marker of free radical-related lipid   peroxidation.57 
Exercise-induced dehydration,   hemoconcentration, and 
altered   acid–base   balance were also reported to be associated 
with this increased membrane permeability.58 Hickman et al 
suggested that transient ischemia induced the development of 
blebs on the cytoplasmic membrane, leading to cTn release.59 
Whatever the mechanism, the kinetics of the asymptomatic 
cTn release after intense exercise with an early peak and 
quick normalization is quite different from the elevation 
pattern observed in acute coronary syndromes.60 Exercise 
duration, exercise intensity, and running distance were the 
suggested risk factors for cTn elevation;61,62 however, it was 
shown that running even a short distance could result in 
significant cTn release in untrained individuals.63 Troponin 
elevation was not found to be associated with any func-
tional impairment using either echocardiography or cardiac 
magnetic resonance imaging.64–66 In light of the current 
knowledge, there seems to be no prognostic implication of 
troponin elevation.
Direct myocardial trauma
Direct cardiac trauma may cause troponin elevation due to 
the impairment of cardiac myocyte integrity. Velhamos et al 
enrolled 333 patients with direct myocardial contusions to 
examine the predictive value of troponin levels.67 Serial 
evaluation of ECG and troponin measurements and selective 
echocardiographic examination revealed that the combined 
use of ECG and cTnT had a negative predictive value of 
100% for blunt cardiac trauma, whereas cTnI alone had a 
negative predictive value of 94%.
Cardiac causes of troponin elevation  
other than acute coronary 
syndromes
Acute pericarditis
Although troponins are not found in the pericardium, they 
may be elevated because of the involvement of the epicar-
dium in the inflammatory process.68,69 In addition, some 
myocardial damage may take place, and the pattern of 
troponin release in acute pericarditis mimics that of acute 
coronary syndromes. One should also keep in mind that 
these two conditions may coexist, meaning that troponins 
cannot be used for the differential diagnosis of acute coro-
nary syndrome and acute pericarditis.70 In contrast to acute 
coronary syndromes, troponin positivity was not associated 
with poor prognosis.
Acute inflammatory myocarditis
Acute myocarditis may mimic MI since chest pain, segmental 
wall motion abnormalities, and myocardial necrosis proven Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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by troponin elevation exist in both conditions.71,72 Smith 
et al reported the rate of troponin positivity as being 34% in 
a study population with biopsy-proven myocarditis.73 It has 
also been found that troponin is more sensitive than CKMB 
and correlates well with the symptoms of heart failure at 
1 month after acute myocarditis. How long the troponins 
remain elevated depends on the inflammation severity.
Tachycardia
Supraventricular or ventricular tachycardia, atrial fibrillation 
with high ventricular response, or any other tachycardia may 
cause troponin elevation by increasing the myocardial   oxygen 
demand without epicardial coronary stenosis. Temporal 
myocyte damage due to hemodynamic compromise is the 
mechanism responsible for this phenomenon.74,75
Elective cardioversion, using direct current shocks of 
up to 1370 V , was not associated with significant troponin 
increase.76 However, multiple shocks for ventricular fibril-
lation during cardiopulmonary resuscitation raise serum 
troponin levels, which makes non-ST-elevation myocardial 
infarction diagnoses difficult.77
False-positive troponin elevation
Troponin measurements are rarely prone to false-positive 
elevation in the absence of cardiac or noncardiac   reasons. 
Fibrin in the specimens or endogenous antibodies interfer-
ing with the immunoassays are the most frequent causes.78 
  Endogeneous antibodies include rheumatoid factor or 
heterophilic antibodies, which develop against animal 
  immunoglobulins. Frequent contact with animals, injection 
of animal antibodies for some imaging and treatment proce-
dures, immunotherapies, vaccinations, and blood transfusions 
may cause the production of interfering antibodies in the 
circulation.79 To prevent interference, use of ultracentrifuga-
tion is proposed, which has been reported to satisfactorily 
decrease the rate of false-positive results.78 Other strategies 
include dilution, use of heterophilic blocking tubes, use of 
immunoglobulin-inhibiting reagents, or precipitation with 
polyethylene glycol.79 Modern immunoassays have been 
developed through the addition of nonspecific blocking 
antibodies to prevent interference; regardless, there may still 
be patients whose conditions exceed the blocking capacity 
of these immunoassays.80
Conclusion
Although cardiac troponins have been accepted as the gold 
standard in the diagnosis and risk stratification of acute 
coronary syndromes, misinterpretation of detectable troponin 
levels in the emergency department or other in-hospital 
  settings may lead to confusion in terms of diagnosis and 
choice of suitable therapy options. Physicians should be 
aware of the nonischemic causes of troponin positivity as 
well as their pathophysiology and clinical impact in an effort 
to prevent unnecessary invasive and noninvasive treatments 
and coronary care unit admissions.
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